InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2026-02-13 | Angus S King, Jr. | senate | Sale | $1,001 - $15,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.18B+44.7% | $45.04B+32.0% | $34.12B | — | — |
| Cost of sales | $11.05B+31.3% | $8.42B+18.9% | $7.08B+6.8% | $6.63B-9.3% | $7.31B |
| Research and development | $13.34B+21.3% | $10.99B+18.0% | $9.31B+29.5% | $7.19B+3.8% | $6.93B |
| Marketing, selling, and administrative | $11.09B+29.1% | $8.59B+16.1% | $7.40B+15.0% | $6.44B+0.1% | $6.43B |
| Acquired in-process research and development | $2.91B-11.3% | $3.28B-13.7% | $3.80B+318.3% | $908.5M | — |
| Asset impairment, restructuring, and other special charges | $484.0M-43.8% | $861.0M+1166.2% | $68.0M | — | — |
| Other—net, (income) expense | $571.0M+160.7% | $219.0M+325.8% | -$97.0M | — | — |
| Costs, expenses, and other | $39.45B+21.9% | $32.36B+17.4% | $27.57B+26.8% | $21.73B-1.9% | $22.16B |
| Income before income taxes | $25.73B+102.9% | $12.68B+93.5% | $6.55B-3.7% | $6.81B+10.6% | $6.16B |
| Income taxes | $5.09B+143.6% | $2.09B+59.1% | $1.31B | — | — |
| Net income | $20.64B+94.9% | $10.59B+102.1% | $5.24B-16.1% | $6.24B+11.9% | $5.58B |
| Basic (in dollars per share) | $23.0M+95.6% | $11.8M+102.1% | $5.8M-16.0% | $6.9M+12.7% | $6.2M |
| Diluted (in dollars per share) | $22.9M+96.0% | $11.7M+101.9% | $5.8M-15.9% | $6.9M+12.7% | $6.1M |
| Basic (in shares) | $897.3M-0.4% | $900.6M+0.0% | $900.2M-99.9% | $901.74B-0.6% | $906.96B |
| Diluted (in shares) | $899.3M-0.5% | $904.1M+0.1% | $903.3M-99.9% | $904.62B-0.8% | $911.68B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.
Jim Cramer Believes “Novo Nordisk Is Going to Lose a Lot of Share on the Pill to Eli Lilly”
3 things to look out for on Thursday
Eli Lilly (LLY) Q1 Earnings: What To Expect
Eli Lilly Slips as Canada Approves Generic Weight-Loss Drug
Eli Lilly Stock Could Rise Sharply After Earnings
Here's How Much Traders Expect Eli Lilly Stock To Move After Earnings
Guggenheim Raises PT on Eli Lilly (LLY) Amid Several Acquisition Deals
Artisan Global Opportunities Fund Q1 2026 Portfolio Activity
Eli Lilly Signs Up To $2.25 Billion AI Gene Editing Deal
Retatrutide Crosses the Surgical Threshold, but the Real Race Has Just Started
Wegovy's Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch